摘要
目的:通过检测Secretagogin(SCGN)在神经内分泌肿瘤组织中的表达,与神经内分泌肿瘤标志物进行比较,探讨SCGN作为临床病理诊断神经内分泌肿瘤标志物的可能性。方法:收集神经内分泌肿瘤181例(包括类癌、小细胞肺癌、肾上腺皮脂腺瘤等共14种)和非内分泌肿瘤198例(包括肺肿瘤共39种)。所有标本分别用SCGN、CD56、Svn、CgA和NSE抗体进行免疫组织化学染色。结果:181例神经内分泌肿瘤中115例SCGN表达阳性,而且在类癌、小细胞肺癌、大细胞神经内分泌癌、癌伴神经内分泌分化、胰腺内分泌肿瘤、垂体腺瘤和甲状腺髓样癌中均呈持续阳性表达,阳性率均高于80%,明显高于CD56、CgA、SYN、NSE。而SCGN在非神经内分泌肿瘤中表达仅为3%。结论:SCGN对神经内分泌肿瘤具有高度特异性和敏感性,可能成为神经内分泌肿瘤标志物。
Objective： To study the possibility of Secretagogin （SCGN） as clinical pathological markers in the neuroendocrine tumors compared with previous neuroendocrine tumour markers. Methodst 181 cases were diagnosed the neuroendocrine tumours,including 14 types in all ,such as carcinoid,small cell lung cancer, adrenal cortical adenoma, etc. AI were IHC stained with SCGN, CD56,Syn,CgA and NSE antibody and compared with the results of non-neuroendocrine tumors. Results： 115 cases expressed SCGN positively. The percentages of positive expression were more than 80% in the carcinoid carcinomas, small cell pulmonary carcinomas, large cell neuroendocrine carcinomas, carcinomas with neuroendocrine differentiation, pancreatic endocrine turnouts, pituitary adenomas and medullary thyroid carcinomas, respectively, Especially, the percentages of positive expression were 90% in small call pulmonary carcinomas. The positive rate was markedly higher than the ones of CgA, Syn and NSE. Conclusion ： SCGN is a new kind of highly specific markers of neuroendocrine tumours, and can be applied to clinical pathology diagnosing of the neuroendocrine tu- mours.
出处
《中国现代普通外科进展》
CAS
2009年第6期481-484,共4页
Chinese Journal of Current Advances in General Surgery
